Table 4.
Select active clinical trials in second-line therapy for advanced and metastatic bladder cancer100
| Study identifier | Phase | Study drug | Start date | Primary endpoint |
|---|---|---|---|---|
| NCT01265940 | I/II | pazopanib + vinflunine | Dec 2010 | PFS |
| NCT00365157 | I/II | E7389 (halichondrin B analog) | October 2010 | Response rate and safety |
| NCT00683059 | II | nab-paclitaxel | May 2008 | Response rate |
| NCT00578526 | II | sunitinib (SPRUCE) | December 2007 | PFS |
| NCT01282463 | II | Docetaxel ± ramucirumab or IMC-18F1 | January 2011 | PFS |
| NCT01234519 | I/II | AEZS-108 in LHRH + urothelial cancers | November 2010 | MTD |
| NCT00722553 | II | pralatrexate | July 2008 | ORR |
| NCT01031875 | II | pazopanib | December 2009 | ORR |
| NCT01108055 | II | pazopanib + paclitaxel | April 2010 | ORR |
| NCT00933374 | II | everolimus + paclitaxel | July 2009 | ORR |
Abbreviations: PFS, progression-free survival; MTD, maximum tolerated dose; ORR, objective response rate; AEZS-108, luteinizing-hormone-releasing hormone linked to doxorubicin.